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ABSTRAK
Tujuan: menilai penggunaan antikoagulan dan implementasi pedoman internasional mengenai profilaksis 
tromboemboli vena (TEV) pada pasien rawat inap dengan penyakit medik akut di Jakarta, Indonesia. 
Metode: studi multisenter, observasional, dengan mendata pasien terdiagnosis penyakit medik akut dan kondisi 
medis lainnya yang berisiko TEV dan menjalani imobilisasi sedikitnya 3 hari. Hasil: dari total 401 pasien, 
hanya 46.9% yang menerima antikoagulan, terdiri atas: unfractionated heparin (64.4%), fondaparinux (11.7%), 
enoxaparin (9.6%), warfarin (3.7%), dan kombinasi antikoagulan (10.6%). Profilaksis TEV dengan metoda fisik 
dan mekanik digunakan pada 81.3% pasien baik tunggal atau dikombinasi dengan antikoagulan. Selama rawat 
inap, TEV didapatkan pada 3.2% pasien. Dari 13 pasien, 10 pasien (2.5%) mengalami TEV di tungkai bawah dan 
3 pasien (0.75%) diduga mengalami emboli paru. Rujukan internasional utama yang digunakan adalah AHA/
ASA 2007 (47.4%), diikuti oleh ACCP 2008 (21.7%). Kesimpulan: studi ini menunjukkan penggunaan profilaksis 
antikoagulan yang kurang. Thromboprofilaksis mekanik baik tunggal atau kombinasi dengan antikoagulan 
merupakan yang tersering digunakan. Unfractionated heparin paling sering dipilih sebagai profilaksis TEV. 
Rujukan tata laksana yang lebih sering digunakan adalah AHA/ASA 2007. Profilaksis TEV pada pasien dengan 
penyakit medik akut perlu ditingkatkan.
Kata kunci: thromboemboli vena (TEV), profilaksis, pendataan, rawat inap bukan operasi.
ABSTRACT
Aim: to assess the current use of anticoagulants and implementation of International Guidelines in venous 
thromboembolism (VTE) prophylaxis in hospitalized patients with acute medical illnesses in Jakarta, Indonesia. 
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Methods: a multicenter, prospective, disease registry, recruiting patients diagnosed as acutely ill medical 
diseases and other medical conditions at risk of VTE, with in-hospital immobilization for at least 3 days. 
Results: of 401 patients, 46.9% received anticoagulants which included unfractionated heparin (64.4%), 
fondaparinux (11.7%), enoxaparin (9.6%), warfarin (3.7%), and combination of anticoagulants (10.6%). 
VTE prophylaxis using physical and mechanical method was used in 81.3% of patients, either as a single 
modality or in combination with anticoagulants. During hospitalization, VTE were found in 3.2% patients; 
10 patients (2.5%) had lower limb events and 3 patients (0.75%) had a suspected pulmonary embolism. The 
main reference international guidelines used were AHA/ASA 2007 (47.4%), followed by ACCP 2008 (21.7%). 
Conclusion: the study showed underutilization of prophylaxis anticoagulants in which mechanical 
thromboprophylaxis either alone or combination with anticoagulants was the most commonly used. 
Unfractionated heparin was the preferable choice. The most commonly used guideline was AHA/ASA 2007. 
VTE thromboprophylaxis in medically ill patients needs to be encouraged.
Key words: venous thromboembolism (VTE), prophylaxis, registry, non-surgery hospitalization.
INTRODUCTION
Ve n o u s  t h r o m b o e m b o l i s m  ( V T E ) 
is commonly found at autopsy in patients 
who received medical treatment and died in 
the hospital. Prophylaxis of VTE has been 
less extensively studied in medical patients 
than in surgical patients, and the use of 
thromboprophylaxis is uncommon in medical 
patients. Even though primary prophylaxis of 
VTE was not standardized therapy in Indonesia, 
this prophylaxis has been implemented in 
orthopedic surgery since year 2000 while some 
clinicians were doing secondary prophylaxis 
of VTE. At least 3 large randomized clinical 
trials have demonstrated the efficacy and safety 
of VTE prophylaxis in the medical setting. 
These studies used enoxaparin (MEDENOX)1, 
dalteparin (PREVENT)2, and fondaparinux 
(ARTEMIS)3 compared to placebo in acutely 
ill medical patients hospitalized with heart 
failure, respiratory failure, infectious disease 
or inflammatory disease. All studies showed a 
significant reduction in the rate of VTE, while 
the rate of major bleeding events was comparable 
to placebo. These results support the evidence-
based recommendations for thromboprophylaxis 
in this clinical setting.
The benefits of these 3 studies should be 
translated into general practice. To facilitate 
its implementation, the medical practitioners 
should be able to readily identify suitable 
patients who would gain most from prophylaxis 
with these anticoagulants and implement 
the best treatment protocols according to 
evidence-based and International Guidelines. 
MEDENOX, PREVENT, and ARTEMIS studies 
demonstrated the benefits of anticoagulants for 
acutely ill medical patients to prevent incidence 
of VTE. International Guidelines (AHA/ASA4, 
ACCP5, ESO6, IUA7) recommended the use 
of anticoagulants for thromboprophylaxis in 
acutely ill medical patients. In Indonesia, there 
is lack of data on the use of anticoagulants 
in this group of patients. We presumed that 
even though all doctors had known about the 
guidelines of anticoagulant prophylaxis, not 
all doctors followed the guidelines properly. 
Besides, we predicted as well that there was 
underutilization of anticoagulant prophylaxis or 
the guidelines were not applied optimally. This 
study would provide data on the appropriate 
use of anticoagulants, International Guidelines 
implementation, demographic data and risk 
factors of patients in the prevention of VTE 
within real clinical settings in Jakarta, Indonesia.
The primary objectives were to assess current 
use of anticoagulants oral or intravenous for VTE 
prophylaxis in hospitalized patients with acute 
medical illnesses and other medical conditions 
at risk of VTE, to assess the underutilization and 
inappropriate use of anticoagulant prophylaxis, 
and to assess International Guidelines 
implementation in VTE prophylaxis in Jakarta, 
Indonesia. The secondary objectives were to 
obtain demographic data of acutely ill medical 
patients who are at risk of VTE events in Jakarta, 
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and to assess VTE prophylaxis method other than 
anticoagulants used in these patients.
METHODS 
Study Design
A multicenter, prospective, disease registry. 
The study protocol was approved by the Ethics 
Committee of the Medical Faculty, University 
of Indonesia.
Patients
Inclusion criteria were 40 years of age and 
older, with a diagnosis of acutely ill medical 
disease or other medical condition at risk of 
VTE, such as acute heart failure (NYHA class 
III / IV), acute respiratory infection, acute 
infective disease (CNS, Hematology), acute 
myocardial infarction, acute ischemic stroke, 
paraparesis/hemiparesis, malignancy. Patients 
were hospitalized for at least 6 days and were 
immobilized for at least 3 days. Patients who 
participated in other clinical study were excluded. 
Written informed consents were obtained from 
the patients before participation in the study.
Treatment
This was an observational study, therefore no 
specific treatment was recommended. Data were 
collected based on physician’s daily practices 
without any intervention or scheduled visit. 
This study was performed without interfering 
with the patient’s routine management. There 
were no study tests or clinical interventions 
performed. If there was any adverse event (AE) 
or serious adverse event (SAE) during visit, 
physician would report this AE or SAE to the 
pharmaceutical company manufacturing the 
product through the Spontaneous Reporting 
Procedure.
Statistical Analysis
Numerical variables were summarized using 
mean and standard deviation, while frequencies 
and percentages are reported for nominal 
variables. These descriptive statistics were 
planned to describe the baseline characteristics 
of subjects, including risk factors, the choice of 
anticoagulants, the reference guidelines, other 
treatments given, and VTE disease found. No 
comparison analysis was made.
RESULTS 
Characteristics of Patients
A total of 401 patients were recruited 
from 18 participating physicians in 7 centers 
from December 2009 until November 2011. 
Characteristics of patients are shown in Table 1.
Table 1. Characteristics of patients (N=401)
Characteristics Mean (SD*)
Age (years) 58.1 (10.96)
Weight (kg) 57.7 (12.40)
BMI (kg/m²) 22.0 (4.47)
Systolic BP (mmHg) 130.0 (26.18)
Diastolic BP (mmHg) 78.0 (14.87)
Heart Rate (bpm) 89.0 (15.4)
Respiratory Rate (time/min) 22.0 (4.77)
Hospital Stay (days) 18.4 (17.27)
Duration of anticoagulant use (days) 10.0 (17.73)
Male, n (%) 248 (61.8)
Female, n (%) 153 (38.2)
Patients at discharge, n (%)
 - Died 74 (18.0)
 - Alive 327 (82.0)
Risk Factors
Majority of the patients had prolonged 
immobilization as risk factor, it was 77.6% (311 
patients). Most of the patients (80.6%) had at 
least 1 risk factor. Only 19.2% had 2 risk factors 
or more as shown in Table 2.
Table 2. Risk factors in baseline characteristics of patients 
(N=401)
Risk Factors N (%)
Prolonged immobilization (>72 hrs) 311 (77.6)
History of malignancy 67 (16.7)
Obesity 45 (11.2)
Age >75 years 30 (7.5)
Trombophilia 11 (2.7)
History of VTE 7 (1.8)
Dehydration 2 (0.5)
Nephrotic syndrome 2 (0.5)
Varicose vein 1 (0.3)
At least 1 risk factor 323 (80.6)
≥2 risk factors 77 (19.2)
No data 1 (0.2)
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Methods of VTE Prophylaxis Used
Methods of VTE prophylaxis used in this 
study were mechanical thrombophylaxis (40.1%), 
pharmacological thrombophylaxis (5.7%), 
combination of mechanical and pharmacologic 
thrombophylaxis (41.1%), others (0.5%), and 
no documented prophylaxis (12.5%) as shown 
in Figure 1. The majority of VTE prophylaxis 
methods used in patients in this study was 
mechanical method or physiotherapy (326 of 
401 patients (81.3%)), either used as a single 
method or in combination with pharmacological 
thrombophylaxis.
Current Use of Anticoagulants in Hospitals 
in Jakarta
From the total of 401 patients, 188 patients 
(46.9%) received prophylaxis anticoagulants, 
and 213 patients (53.1%) did not. Figure 2 
shows the reasons for not using anticoagulants 
resulting in underutilization of anticoagulant 
prophylaxis, in which 37 of 213 patients (17.5%) 
were contraindicated, 22 patients (10.4%) were 
concerned for bleeding, 99 patients (46.2%) 
had no anticoagulant indication (based on the 
doctors’ opinion despite strong indication of 
anticoagulant prophylaxis in patients with >6 
days bedridden), 45 patients (21.2%) for cost 
reasons, and 10 patients (4.7%) for other reasons.
Initial Choice of Anticoagulant
Table 3  shows the initial choice of 
anticoagulants as VTE prophylaxis. Initial 
choice of anticoagulants among the 188 patients 
were unfractionated heparin (UFH) in 121 
patients (64.4%), low molecular weight heparin 
(enoxaparin) in 18 patients (9.6%), synthetic 
pentasaccharide (fondaparinux) in 22 patients 
(11.7%), oral anticoagulant (warfarin) in 7 patients 
(3.7%), and more than 1 anticoagulants in 20 
patients (10.6%).
Figure 1. Methods of VTE prophylaxis used in this study
Figure 2. Reasons for not using anticoagulants
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Signs or Symptoms of VTE
Signs or symptoms of VTE were found during 
hospitalization in 13 patients among the total 
of 401 patients (3.2%), deep vein thrombosis 
(DVT) at lower limbs were found in 11 patients 
(edema in 2 patients, edema and pain in 2 
patients, and edema, pain, red skin and changes 
in skin temperature in 7 patients), and suspected 
pulmonary embolism was found in 2 patients 
(apnea in 1 patient, dyspnea and quick breathing 
in 1 patient). In one patient, both local and general 
signs and symptoms of VTE were found.
In 13 patients with VTE, the median of length 
of stay in hospital is 20 days with range 2-103, 
the detail of the patient’s length of stay and site 
can be found in Table 4. 
Among these 13 patients, 10 patients 
received UFH, 1 patient received fondaparinux, 
1 patient received enoxaparin and warfarin, 1 
patient did not receive anticoagulant and 10 
patients were on mechanical VTE prophylaxis. 
One patient who did not receive anticoagulant 
is patient with hepatic fibrosis, massive ascites, 
and hepatic encephalopathy, therefore the 
patient was considered to be contraindicated 
to anticoagulant. The patient then died due to 
suspected pulmonary embolism, since the patient 
showed sign or symptom of apnea, despite on 
mechanical VTE prophylaxis.
In the meantime, 12 patients who received 
VTE prophylaxis anticoagulant, 5 patients died 
from their underlying diseases. Six of those 12 
patients with signs or symptoms of VTE had 
underwent duplex ultrasound examination which 
showed venous thrombus in 2 patients, 1 patient 
with vein valve insufficiency, and no observed 
venous thrombus in 3 patients. The other 6 
patients did not undergo duplex ultrasound 
examination due to various reasons (the signs 
of thrombosis were already clear in 1 patient, 
patients were treated directly in 2 patients, 
unconsciousness in 1 patient, the ultrasound has 
been performed previously in 1 patient, and no 
data in 1 patient). 
Bleeding Complications
The rate of major bleeding during 
anticoagulant treatment in this group (188 
patients) was 2.1% (4 patients), 3 patients 
received UFH and 1 patient received LMWH, 
while the rate of minor bleeding in gum, skin 
and gaster was 0.5% (1 patient) each, with 8.5% 
hematuria (16 patients), and 0.5% (1 patient) had 
decreased hemoglobin without any bleeding, and 
another 0.5% (1 patient) had prolonged APTT 
(> 3 x control). 
Current International Guidelines Used
Figure 3 shows the reference International 
Guidelines used in prescribing anticoagulant 
prophylaxis in this study. They were AHA/
ASA 2007 in 190 patients (47.4%), for which 
anticoagulants were used in 118 patients and not 
used in 72 patients, followed by ACCP 2008 in 
87 patients (21.7%), where anticoagulants were 
used in 45 patients and not used in 42 patients. 
AHA/ASA 2007 and ACCP 2008 combination 
was used in 98 patients (24.4%), in which 
anticoagulants were used in 21 patients and not 
used in 77 patients. Whereas ESO 2008 was used 
in 24 patients (6.0%), and IUA 2006 in only 1 
patient (0.2%). 
DISCUSSION
Current Use of Anticoagulants in Hospitals 
in Jakarta 
In this study, the risk factors in baseline 
characteristics of patients referred to MEDENOX 
study, which were immobilization and acute 
infection, while others factors were age, 
malignancy, previous history of VTE, and 
obesity.1 There were some additional risk factors 
which were thrombophilia, varicose vein, 
pregnancy/postpartum8, nephrotic syndrome9, 
and dehydration.10 Meanwhile, thrombocytosis, 
previously considered as a risk factor for VTE, 







More than 1* 20 (10.6)
*enoxaparin, UFH (9); enoxaparin, warfarin (1); enoxaparin, 
fondaparinux (3); enoxaparin, UFH, warfarin (1); UFH, 
warfarin (5); UFH, fondaparinux (1)
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Table 4. List of patients with VTE
Site
Length of stay 
in hospital 
(days)
Sex Age Anticoagulant Mechanical thrombophylaxis Underlying diseases
Hematology 11 Female 53 UFH 25000 U/24 hours Yes
Deep vein thrombosis lower 
extremities, cellulitis, abscess, 
type 2 diabetes mellitus
Hematology 22 Male 60 UFH 20000 U/24 hours Yes
Irreversible shock, sepsis, 
hospital associated pneumonia, 
prostate adenocarcinoma, type 2 
diabetes mellitus
Hematology 34 Female 47 UFH 3x5000 U No Lymphoma malignum




Yes Complete fracture simphisis ramus superior inferior
Hematology 23 Female 45 UFH 20000 U/24 hours Yes Breast cancer stage IV
Hematology 103 Male 45 UFH 10000 U/24 hours Yes
Non ST elevation myocardial 
infarction, chronic kidney 
disease on hemodialysis, 
hypertension, deep vein 
thrombosis
Neurology 58 Male 68 Fondaparinux 1x2.5 mg Yes
Hypertension grade I, glaucoma 
ocular dextra and sinistra, 
hypokalemia, suspect peripheral 
arterial disease
Neurology 20 Male 51 UFH 10000 U/24 hours Yes
Deep vein thrombosis, 
congestive heart failure fc III-IV, 
peripheral arterial disease, 
cardiogenic shock
Neurology 32 Female 44 UFH 20000 U/24 hours Yes
Suspect thrombosis, deep vein 
thrombosis left leg, coronary 
arterial disease
Cardiology 4 Male 54 - Yes Hepatic cirrhosis, pulmonary embolism





Pulmonary embolism, pulmonary 
tuberculosis, type 2 diabetes 
mellitus





Type 2 diabetes mellitus, 
hypertension, deep vein 
thrombosis





Deep vein thrombosis, diabetic 
neuropathy, bilateral CVC, type 
2 diabetes
was excluded from analysis due to no established 
supporting data. This finding is somewhat 
different to MEDENOX study which found that 
most patients (>50%) had at least 2 risk factors.
Use of Anticoagulants and VTE
In this study, 46.9% patients received 
prophylaxis anticoagulants, and 53.1% patients 
did not. Among those who did not receive 
anticoagulants, the most frequent reason was 
no anticoagulant indication in about half of 
them (46.2%). This was contradictory to the 
eligibility criteria of patients entering this study 
with VTE prophylaxis. The other reasons were 
cost, contraindications, concerned for bleeding 
and others as shown in Figure 2.
Physicians identified that 46.2% of 213 
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patients had no anticoagulant indication and 
did not use anticoagulants to the patients. 
This finding represents lack of compliance of 
physician to start with anticoagulant prophylaxis 
as mentioned in reference guidelines.
VTE incidence in this study was lower 
than those in other studies. Patients in the other 
studies (MEDENOX, ARTEMIS, PREVENT) 
had higher risk of VTE on the whole (10.19% 
in MEDENOX, 8.07% in ARTEMIS, 3.84% in 
PREVENT) because the proportion of VTE risk 
factors such as age (73 years in MEDENOX, 74.7 
years in ARTEMIS, 68.5 years in PREVENT, 
58.1 years in this study), history of VTE (9.44% 
in MEDENOX, 4.59% in ARTEMIS, 3.86% in 
PREVENT, 1.8% in this study), obesity (20.15% 
in MEDENOX, 30.37% in PREVENT, 11.2% 
in this study), and varicose vein (25.32% in 
MEDENOX, 27.63% in PREVENT, 0.3% in 
Table 5. Minor bleeding complications





Decreased Hemoglobin without bleeding 1 (0.5)
Prolonged APTT 1 (0.5)
this study).1-3 Table 6 shows the comparison of 
characteristics of previous studies with this study.
The description of incidence VTE (based on 
signs and symptoms) and types of prophylaxis is 
shown in Table 7. We did not conduct analysis of 
VTE prophylaxis and VTE incidence in our study 
since the study was not designed to compare the 
incidence and also because of group population 
imbalance especially the types of prophylaxis 
given to the subjects.
Initial Choice of Anticoagulants as VTE 
Prophylaxis
Most of the physicians chose UFH as VTE 
prophylaxis in this study because of safety 
concern. Among 138 patients receiving UFH 
(either alone or in combination therapy), the 
main reason for choosing UFH was controllable 
administration in 107 patients (78%). The other 
reason was its low cost in 53 patients (39%). 
The main reason for choosing enoxaparin among 
32 patients was its practical use in 27 patients 
(84%), followed by its safety in 9 patients (28%). 
The main reason for choosing fondaparinux was 
patient request in 22 of 26 patients (85%), while 
for warfarin, it was more practical (oral use) in 
5 of 8 patients (63%).
Methods of VTE prophylaxis used in this 
study were mechanical thrombophylaxis, 
pharmacological thrombophylaxis,  and 
Figure 3. Reference international guidelines used in this study
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combination of mechanical and pharmacologic 
thrombophylaxis, and others. Mechanical 
thromboprophylaxis as a sole prophylaxis measure 
was used only in cases of contraindications 
to the anticoagulants and in cases of high risk 
of bleeding. In the latter cases, mechanical 
thromboprophylaxis was used until the bleeding 
risk has decreased and at this time anticoagulants 
is substituted for or added to the mechanical 
thromboprophylaxis. In the absence of 
contraindications, a combination of mechanical 
and pharmacologic thromboprophylaxis is 
suggested.4-7
Despite of lower risk condition, patients 
receiving anticoagulants in this study, had a 
similar incidence of VTE as in MEDENOX 
and Artemis studies (4.8 % Vs 5.5% and 5.6%). 
It should be noted that the use of mechanical 
thromboprophylaxis in this study was high 
(81.3%), while it is use in MEDENOX and 
Artemis studies was depended on the usual 
practice at each center but the extant was not 
specified. The low prescription of anticoagulants 
by the prescribing physicians, but the high use 
of mechanical thromboprophylaxis in this study 
revealed that there was a great need for VTE 
prophylaxis, which was actually realized by 
the physicians, but they were reluctant to use 
anticoagulants, primarily because of concern 
for bleeding, and not because there was no 
indication.1,3
Bleeding Complication
Even there was a major and minor bleeding 
there was no patients reported died despite of 
the bleeding complications. It seems that the use 
of anticoagulant did not raise significant safety 
concern, since five (5) patients died due the 
underlying disease as we mention above.
Implementation of International Guidelines 
on VTE Prophylaxis in Jakarta 
As previously described, there are 4 
(four) international guidelines used on VTE 
prophylaxis: ACCP 2008, AHA/ASA 2007, ESO 
2008 and IUA 2006. AHA/ASA 2007 was the 
most frequent of international guideline used 
(47.4%, Figure 3) in this study.
However,  despi te  ant icoagulant  is 
recommended in the guidelines, around half of the 
patients (49.06%) were given anticoagulant. This 
Table 6. Comparison of VTE prophylaxis studies
MEDENOX PREVENT ARTEMIS TROPHY
Design RCT, multicenter, in 9 
countries
RCT, multicenter, in 26 
countries





Subjects AIM patients, >40 years, 
hospitalization of ≥6 days
AIM patients, aged ≥40 
years,  hospitalization of 
≥4 days
AIM patients, ≥60 
years, hospitalization of 
≥4 days
AIM patients, ≥40 
years, hospitalized ≥6 
days
Prophylaxis 20 mg or 40 mg of 
enoxaparin
5000 IU of dalteparin 2.5 mg of fondaparinux Various regimens
Outcomes Lower VTE incidence in 
group receiving 40 mg of 
enoxaparin (5.5%) than 
placebo (14.9%). 
Lower VTE incidence 
in group receiving 
prophylaxis (2.77%) than 
placebo (4.96%).
Lower VTE incidence 
in group receiving 
prophylaxis (5.6%) than 
placebo (10.5%). 
Thirteen patients 
(3.2%) of 401 
patients had signs or 
symptoms of VTE 
RCT: randomized controlled trial; AIM: acutely ill medical
Table 7. VTE incidence and types of prophylaxis
Mechanical prophylaxis Medical prophylaxis Mechanical and medical prophylaxis No prophylaxis Total
VTE 1 4 8 0 13
Non VTE 159 21 162 46 388
Total 160 25 170 46 401
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reflects underutilization of the guidelines. Even 
there is strong indication to use anticoagulant, 
only half use the guidelines. Even if they use 
the recommendation only half fully follow 
the guidelines. Others who partially use the 
guidelines, due to many reasons.
According to ESO and IUA Guidelines, 
use of anticoagulants in ischemic stroke 
is not recommended, due to the benefit of 
the anticoagulants are counterbalanced by 
the intracranial hemorrhage. In this setting, 
as in hemorrhagic stroke,  mechanical 
thromboprophylaxis is recommended.6,7
Languasco et al.11 found that underuse and 
inappropriate VTE prophylaxis in Argentina. 
They found that 85.5% of the subjects received 
medical prophylaxis but only 60.6% of the 
subjects received appropriate prophylaxis. VTE 
prophylaxis coverage (46.9%) in our study is 
lower than this study.11
The summary of a anticoagulant treatment 
according to several International guidelines 
for VTE prophylaxis in medical ill patients is 
shown in Table 9.
Unfortunately, there are no available regional 
guidelines either in Asia or South East Asia, as 
well as national guidelines.
Table 8. Comparison of guideline implementation
Languasco et al (2011) TROPHY
Subject 310 prescriptions of 
medical general-ward 
admitted patients
401 acutely ill 
medical patients, 
aged ≥40 years, 
hospitalized for ≥6 
days, immobilized 
for ≥3 days
Result 265 subjects 
(85.5%) received 
thromboprophylaxis, 188 
subjects (60.6%) of these 
265 subjects received 
appropriate prophylaxis 
according to the 
institutional guidelines, 





Table 9. Summary of anticoagulant treatment according to selected international guidelines for VTE prophylaxis in medically 
ill patients













Confined to bed and 
have one or more 
risk factors (active 
cancer, previous 
VTE, sepsis, acute 
neurologic disease, 




high risk of DVT 
or pulmonary 
embolism 




 - Age > 40 years old with 
acutely medical illness and/
or reduced mobility with one 
of morbidities : CHF class III/
IV, respiratory disease, active 
cancer requiring therapy, acute 
infective disease, rheumatic 
disease, ischemic stroke, or 
acute myocardial infarction;
 - Acute medical illness with 
reduced mobility and one of 
the risk factors : history of VTE, 
malignant disease, or age over 
75 years old.
Choices of Anticoagulants




Grade IA Grade IA Grade A (enoxaparin 40 mg od / 
dalteparin 5.000 U od)
LDUH Grade IA Grade IA Grade A (UFH 5.000 IU tid)
Fondaparinux Grade IA (not specified) Grade B (2.5 mg daily dose)
CHF, congestive heart failure; DVT, deep vein thrombosis; LMWH: Low molecular weight heparin; LDUH, low dose 
unfractionated heparin
* for ischemic stroke
+ Grade A: recommendations are based on level 1 evidence from randomized controlled trials with consistent results. 
Grade B: recommendations are based on level 1 evidence from randomized controlled trials with less consistent results, 
limited  power, or other methodological problems. Grade C: recommendations are based on level 2 evidence from well-
conducted observational studies with consistent results.
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CONCLUSION
The present thromboprophylaxis registry in 
Jakarta, Indonesia, among acutely ill medical 
patients at risk of VTE showed underutilization 
of prophylaxis anticoagulant. This registry also 
showed underutilization of LMWH compared to 
UFH. AHA/ASA guideline is the most commonly 
used guideline for VTE prophylaxis, followed by 
ACCP guideline. The reasons of underutilization 
of anticoagulant prophylaxis were medical 
reasons (74.1%) which also included doctors’ 
opinion, cost (21.2%), and other reasons 
(4.7%). Mechanical thromboprophylaxis either 
alone or in combination with pharmacological 
thromboprophylaxis is the most commonly used 
in this study population. VTE thromboprophylaxis 
strategy in medically ill patients needs to be 
improved in clinical setting.
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